EU regulators back climate-friendly inhaler
Drugmaker AstraZeneca said the new inhaler has a fraction of the carbon footprint of its existing model, which uses a gas propellant to deliver a dose of medicine to patients and is already available in the European Union for adults with chronic obstructive pulmonary disease (COPD).
These types of inhalers may be small, but they pack a powerful punch, producing the same type of greenhouse gas as air conditioning and heat pumps. In the United Kingdom, they cause 3 per cent of the National Health Service's (NHS) overall carbon emissions, according to Asthma + Lung UK.
Many of these gases are now being phased out in the EU for environmental reasons, according to the European Medicines Agency (EMA).
An EMA advisory committee issued a positive opinion of the new inhaler on Friday, and the European Commission, the EU's executive body, will make a final decision in the coming months.
Other inhalers that do not use gas propellants are already available, and AstraZeneca's new model has a similarly low carbon footprint.
The new option 'means patients and their clinicians now don't need to feel like they have to choose between the most appropriate treatment and the planet,' Pablo Panella, AstraZeneca's senior vice president of global respiratory and immunology, said in a written comment to Euronews Health.
The new inhaler is already available in the United States, China, and Japan, and the United Kingdom signed off in May.
AstraZeneca said it plans to transition its inhalers to the new model across the EU in the coming months, and that it hopes to roll the model out worldwide by 2030.
The EMA said it 'works the same way and gives the same results in the lungs and the body [as] the product currently on the market'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 days ago
- Euronews
The battle for the EU budget - who wins, who loses?
Brussels has spoken! The European Commission presented its long-term budget proposal, kicking off tough negotiations over who gets what and who pays for it. Rich countries like Germany and the Netherlands have already rejected the numbers game as being too ambitious. But it's not only about politics - it's about who wins and who loses in crucial areas like technology, agriculture and climate action. Who will finally get their way? And what are the benefits for ordinary citizens? Questions for our panel this week: Kait Bolongaro, managing editor for Europe at MLEX, Tomi Huhtanen, executive director at the Wilfried Martens Centre and Dave Keating, Brussels correspondent for France 24. To say that the European Commission's proposal for a long-term budget would not survive in its current form, would be an understatement. For Chancellor Friedrich Merz the EU must do more with the money it has. This sets up a clash with fellow German Christian Democrat Ursula von der Leyen who believes that rising challenges need an adequate fiscal response - in other words: more money. Get ready for bruising budget battles that might last two years! Another fight over money: This time, it would make smoking, in all its forms, more expensive. The EU Commission announced a renewed push to curb tobacco consumption through higher taxation. At the same time, the World Health Organization is sounding the alarm bell: chronic public health problems are getting out of hand. As a remedy, the WHO is pushing countries to raise the prices of sugary drinks, alcohol and tobacco by 50 percent over the next ten years through higher taxes. This would save millions of lives and raise 1.4 trillion dollars globally, according to the WHO. The move would help cut consumption of the products which contribute to diseases like diabetes and cancer. The WHO is now becoming an ally for the European Commission, which wants to modernize the EU's Tobacco Taxation Directive. A strong signal for public health or just another way to squeeze taxpayers? Can public health be improved by fiscal measures? Finally, panellists discuss the fast-fashion industry operating in Eurpope, as the hunt for super-cheap online bargains might get a little less attractive - at least in France. The government in Paris has hit Chinese ultra-fast fashion giant SHEIN with a €40 million fine for what regulators call 'deceptive commercial practices.' It's a major escalation in Europe's scrutiny of the fast fashion model. The blow comes two months after the European Commission found Shein guilty of engaging in illegal commercial practices under EU law, following a coordinated investigation with national consumer protection authorities. And earlier this year, France already presented new legislation targeting Shein and its Chinese rival Temu, imposing eco-taxes, advertising bans and influencer restrictions. Will these steps have an impact among consumers? Will they stop buying from those sites?
Euronews
3 days ago
- Euronews
EU regulators back climate-friendly inhaler
European regulators have given their backing to a new eco-friendly inhaler that could help curb health care's climate impact. Drugmaker AstraZeneca said the new inhaler has a fraction of the carbon footprint of its existing model, which uses a gas propellant to deliver a dose of medicine to patients and is already available in the European Union for adults with chronic obstructive pulmonary disease (COPD). These types of inhalers may be small, but they pack a powerful punch, producing the same type of greenhouse gas as air conditioning and heat pumps. In the United Kingdom, they cause 3 per cent of the National Health Service's (NHS) overall carbon emissions, according to Asthma + Lung UK. Many of these gases are now being phased out in the EU for environmental reasons, according to the European Medicines Agency (EMA). An EMA advisory committee issued a positive opinion of the new inhaler on Friday, and the European Commission, the EU's executive body, will make a final decision in the coming months. Other inhalers that do not use gas propellants are already available, and AstraZeneca's new model has a similarly low carbon footprint. The new option 'means patients and their clinicians now don't need to feel like they have to choose between the most appropriate treatment and the planet,' Pablo Panella, AstraZeneca's senior vice president of global respiratory and immunology, said in a written comment to Euronews Health. The new inhaler is already available in the United States, China, and Japan, and the United Kingdom signed off in May. AstraZeneca said it plans to transition its inhalers to the new model across the EU in the coming months, and that it hopes to roll the model out worldwide by 2030. The EMA said it 'works the same way and gives the same results in the lungs and the body [as] the product currently on the market'.
Euronews
3 days ago
- Euronews
EU regulator backs new Alzheimer's drug, months after rejecting it
The European Union's medicines regulator is reversing course on its decision to block a new Alzheimer's disease treatment, saying the drug can be offered to certain patients under strict safety protocols. In late March, the European Medicines Agency's (EMA) drug evaluators said the risks did not outweigh the benefits for the medicine donanemab, which can slow the progression of early-stage Alzheimer's but also raises the risk of potentially deadly brain swelling and bleeding. But in a revised opinion on Friday, the group said donanemab can be offered to a specific subset of Alzheimer's patients in tightly controlled settings. Donanemab, which is sold by Eli Lilly as Kisunla, is a monoclonal antibody taken via a once-monthly infusion. It's already been approved in the United Kingdom, the United States, Japan, and China. In a clinical trial, Kisunla slowed dementia symptoms by up to 35 per cent over 18 months – but three people died with serious amyloid‑related imaging abnormalities (ARIA), which are a common side effect of the medicine that can cause swelling and bleeding in the brain. Two of these patients carried a type of gene that raises the risk of Alzheimer's, and Lilly had suggested that the medicine only be offered to people who do not have the gene. In March, the EMA committee said that people without the gene were still at risk of fatal complications from ARIA. On Friday, the group said the drug can be offered to early Alzheimer's patients who have at most one copy of the gene – but only in a controlled access programme with medical teams that know how to detect and treat ARIA. Patients must also start at a lower dose. The EMA said that with those measures in place, its advisory group 'concluded that Kisunla's benefits outweigh its risks in noncarriers and people with just one copy' of the gene. The European Commission has the final say on whether a new drug or vaccine is approved, but it usually adopts the EMA evaluators' recommendations. That's why drugmaker Lilly had asked the EMA group to reconsider its negative opinion on Kisunla. It argued that ARIA is usually temporary and does not cause symptoms in most cases. Alzheimer's groups were also disappointed by the initial decision. At the time, Alzheimer Europe said that while patient safety is important, strict prescribing rules and safety monitoring could help ensure dementia patients have access to the new drug while keeping it away from those at higher risk of serious side effects. Notably, the EMA and the Commission recently greenlit another Alzheimer's drug, Leqembi, that comes with similar side effects for people with the gene. In that case, the EMA group had also first refused the drug, but later recommended that it be offered to people with only one or no copies of the gene – making it the first medicine of its kind authorised in the EU. The Commission is expected to make a final decision on Kisunla in the coming months.
